What is it about?
This study explores how turning off a gene called Steroid Receptor Coactivator-3 (SRC-3) in regulatory T cells empowers the immune system to destroy several aggressive cancers in mice. By removing SRC 3, these immune cells switch from suppressing immune activity to activating a strong anti-tumor response, leading to the elimination of glioblastoma, melanoma, and lung tumors without causing harmful immune side effects.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Why is it important?
This work is significant because it identifies a novel strategy to convert “immune-cold” tumors into “immune-hot” tumor microenvironments across multiple solid cancers that are typically resistant to current therapies. By disabling the SRC-3 gene in regulatory T cells, the study demonstrates that several aggressive tumors can be eradicated in mice without inducing detrimental immune-related side effects. These findings highlight a promising immunotherapeutic approach that may benefit patients whose cancers do not respond to existing checkpoint inhibitors.
Perspectives
These findings suggest that SRC-3 KO Treg cells may represent a novel avenue for cancer immunotherapy. By reprogramming Tregs from immunosuppressive to immune-activating cells, this strategy has the potential to treat tumors that are unresponsive to current checkpoint inhibitors. Notably, this approach did not induce immune-related adverse effects in mice, supporting the possibility of a safer therapeutic option. Future studies will investigate how SRC-3 KO Tregs remodel diverse tumor microenvironments, whether this strategy can prevent tumor recurrence, and how it can be translated into clinical therapies for patients with hard-to-treat solid tumors.
Sang Jun Han
Baylor College of Medicine
Read the Original
This page is a summary of: Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models, OncoImmunology, March 2026, Taylor & Francis,
DOI: 10.1080/2162402x.2026.2640261.
You can read the full text:
Resources
Contributors
The following have contributed to this page
